Pharmaceutical companies by P/E ratio
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Takeda Pharmaceutical leads the 33 pharmaceutical companies ranked by P/E ratio, at 304, ahead of Merck & Co (139) and Ligand Pharmaceuticals (120). Figures as of 18 Nov 2026, 22:17 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 33
- First
- Takeda Pharmaceutical304
- Median
- 40.1
- Combined market value
- NOK 48.97T
- Countries
- 10
- Not ranked
- 28no P/E ratio on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | P/E ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Takeda PharmaceuticalTAK · Health Care | 304 | NOK 657.8B | NOK 205.90 | 1.71% down | 54% up | ||
| 2 | Merck & CoMRK · Health Care | 139 | NOK 3.29T | NOK 1,333.75 | 3.90% down | 51% up | ||
| 3 | Ligand PharmaceuticalsLGND · Health Care | 120 | NOK 57.8B | NOK 2,891.59 | 1.67% up | 43% up | ||
| 4 | TG TherapeuticsTGTX · Health Care | 98.7 | NOK 96.7B | NOK 640.06 | 5.44% up | 107% up | ||
| 5 | Teva Pharmaceutical IndustriesTEVA · Health Care | 98.2 | NOK 477B | NOK 408.80 | 0.92% down | 74% up | ||
| 6 | Jazz PharmaceuticalsJAZZ · Health Care | 73.3 | NOK 154B | NOK 2,398.48 | 2.93% up | 37% up | ||
| 7 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | 72.0 | NOK 72.3B | NOK 920.11 | 0.06% down | 126% up | ||
| 8 | Amneal PharmaceuticalsAMRX · Health Care | 54.7 | NOK 73.8B | NOK 211.80 | 3.60% up | 83% up | ||
| 9 | BeOne MedicinesONC · Health Care | 51.7 | NOK 446.3B | NOK 3,906.96 | 2.34% down | 17% up | ||
| 10 | Corcept TherapeuticsCORT · Health Care | 51.0 | NOK 71.8B | NOK 656.23 | 3.25% down | 8% down | ||
| 11 | AbbVieABBV · Health Care | 49.1 | NOK 4.89T | NOK 2,768.65 | 2.33% down | 26% up | ||
| 12 | Royalty PharmaRPRX · Health Care | 44.9 | NOK 382.2B | NOK 664.74 | 0.01% down | 78% up | ||
| 13 | Eli LillyLLY · Health Care | 44.9 | NOK 11.92T | NOK 13,385.39 | 2.32% down | 35% up | ||
| 14 | GenmabGMAB · Health Care | 43.6 | NOK 304.2B | NOK 493.40 | 1.91% down | 70% up | ||
| 15 | Dr. Reddy's LaboratoriesRDY · Health Care | 41.6 | NOK 120.9B | NOK 145.01 | 1.28% up | 5% up | ||
| 16 | Johnson & JohnsonJNJ · Health Care | 41.4 | NOK 6.35T | NOK 2,639.81 | 2.15% down | 38% up | ||
| 17 | PfizerPFE · Health Care | 40.1 | NOK 1.55T | NOK 271.63 | 1.44% down | 14% up | ||
| 18 | Abbott LaboratoriesABT · Health Care | 39.0 | NOK 1.75T | NOK 1,011.39 | 0.22% down | 17% down | ||
| 19 | Vertex PharmaceuticalsVRTX · Health Care | 34.5 | NOK 1.32T | NOK 5,192.98 | 0.42% up | 27% up | ||
| 20 | NovartisNVS · Health Care | 29.6 | NOK 2.84T | NOK 1,502.47 | 2.46% down | 25% up | ||
| 21 | Protagonist TherapeuticsPTGX · Health Care | 26.9 | NOK 80.3B | NOK 1,230.94 | 2.00% up | 46% up | ||
| 22 | AstraZenecaAZN · Health Care | 25.3 | NOK 2.68T | NOK 1,730.45 | 1.93% down | 2% up | ||
| 23 | SanofiSNY · Health Care | 23.4 | NOK 1.1T | NOK 456.13 | 0.86% down | 4% down | ||
| 24 | United TherapeuticsUTHR · Health Care | 21.8 | NOK 238B | NOK 5,588.81 | 1.16% down | 23% up | ||
| 25 | Regeneron PharmaceuticalsREGN · Health Care | 20.9 | NOK 946.9B | NOK 9,152.99 | 1.28% down | 36% up | ||
| 26 | Ascendis PharmaASND · Health Care | 17.8 | NOK 171.7B | NOK 2,616.87 | 0.32% down | 28% up | ||
| 27 | GSKGSK · Health Care | 16.9 | NOK 942.6B | NOK 470.27 | 1.34% down | 6% up | ||
| 28 | ZoetisZTS · Health Care | 14.6 | NOK 336.6B | NOK 828.34 | 2.50% up | 29% down | ||
| 29 | Bristol-Myers SquibbBMY · Health Care | 13.2 | NOK 1.18T | NOK 576.56 | 2.92% down | 34% up | ||
| 30 | GrifolsGRFS · Health Care | 10.2 | NOK 55.8B | NOK 81.99 | 1.85% down | 1% up | ||
| 31 | Novo NordiskNVO · Health Care | 10.0 | NOK 1.68T | NOK 381.69 | 3.12% down | 17% down | ||
| 32 | Alnylam PharmaceuticalsALNY · Health Care | 7.5 | NOK 193.7B | NOK 1,446.23 | 4.54% down | 66% down | ||
| 33 | Edgewise TherapeuticsEWTX · Health Care | 4.9 | NOK 43.8B | NOK 400.47 | 1.59% down | 88% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 9.6803 NOK). 28 companies have no P/E ratio on file and are not ranked here.
Questions and answers
Which pharmaceutical companies rank first by P/E ratio?
Takeda Pharmaceutical (304), Merck & Co (139) and Ligand Pharmaceuticals (120) are the top three of the 33 pharmaceutical companies ranked by P/E ratio as of 18 Nov 2026, 22:17 UTC.
How many pharmaceutical companies are in this ranking?
33 are ranked by P/E ratio. 28 more have no P/E ratio on file and are left out rather than ranked at zero.
What are these pharmaceutical companies worth together?
The 33 pharmaceutical companies ranked by P/E ratio have a combined market value of NOK 48.97T as of 18 Nov 2026, 22:17 UTC.
What does ranking by P/E ratio measure?
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Pharmaceutical companies by P/E ratio”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=pe-ratio
Underlying data: Yahoo Finance; SEC EDGAR.